Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count

Amanda Mocroft; Peter Reiss; Ole Kirk; Cristina Mussini; Enrico Girardi; Philippe Morlat; Christoph Stephan; Stephane De Wit; Katja Doerholt; Jade Ghosn; Heiner C Bucher; Jens D Lundgren; Genevieve Chene; Jose M Miro; Hansjakob Furrer; Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)

doi:10.1086/655761

Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count

Amanda Mocroft, Peter Reiss, Ole Kirk, Cristina Mussini, Enrico Girardi, Philippe Morlat, Christoph Stephan, Stephane De Wit, Katja Doerholt, Jade Ghosn, Heiner C Bucher, Jens D Lundgren, Genevieve Chene, Jose M Miro, Hansjakob Furrer, Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)

Graduate School of Health and Medical Sciences

Research output: Contribution to journal › Journal article › Research › peer-review

99 Citations (Scopus)

Abstract

Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.

Original language	English
Journal	Clinical Infectious Diseases
Volume	51
Issue number	5
Pages (from-to)	611-9
Number of pages	9
ISSN	1058-4838
DOIs	https://doi.org/10.1086/655761 https://doi.org/10.1086/655761
Publication status	Published - 1 Sept 2010

Keywords

AIDS-Related Opportunistic Infections
Adult
Anti-HIV Agents
Antifungal Agents
CD4 Lymphocyte Count
Europe
Female
HIV Infections
Humans
Incidence
Male
Middle Aged
Pneumocystis jirovecii
Pneumonia, Pneumocystis
Risk Factors

Access to Document

Cite this

Mocroft, A., Reiss, P., Kirk, O., Mussini, C., Girardi, E., Morlat, P., Stephan, C., De Wit, S., Doerholt, K., Ghosn, J., Bucher, H. C., Lundgren, J. D., Chene, G., Miro, J. M., Furrer, H., & Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) (2010). Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count. Clinical Infectious Diseases, 51(5), 611-9. https://doi.org/10.1086/655761, https://doi.org/10.1086/655761

Mocroft, A, Reiss, P, Kirk, O, Mussini, C, Girardi, E, Morlat, P, Stephan, C, De Wit, S, Doerholt, K, Ghosn, J, Bucher, HC, Lundgren, JD, Chene, G, Miro, JM, Furrer, H & Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) 2010, 'Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count', Clinical Infectious Diseases, vol. 51, no. 5, pp. 611-9. https://doi.org/10.1086/655761, https://doi.org/10.1086/655761

@article{99879f02eb7140029bf2edda39b75689,

title = "Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count",

abstract = "Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.",

keywords = "AIDS-Related Opportunistic Infections, Adult, Anti-HIV Agents, Antifungal Agents, CD4 Lymphocyte Count, Europe, Female, HIV Infections, Humans, Incidence, Male, Middle Aged, Pneumocystis jirovecii, Pneumonia, Pneumocystis, Risk Factors",

author = "Amanda Mocroft and Peter Reiss and Ole Kirk and Cristina Mussini and Enrico Girardi and Philippe Morlat and Christoph Stephan and {De Wit}, Stephane and Katja Doerholt and Jade Ghosn and Bucher, {Heiner C} and Lundgren, {Jens D} and Genevieve Chene and Miro, {Jose M} and Hansjakob Furrer and {Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)}",

year = "2010",

month = sep,

day = "1",

doi = "10.1086/655761",

language = "English",

volume = "51",

pages = "611--9",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count

AU - Mocroft, Amanda

AU - Reiss, Peter

AU - Kirk, Ole

AU - Mussini, Cristina

AU - Girardi, Enrico

AU - Morlat, Philippe

AU - Stephan, Christoph

AU - De Wit, Stephane

AU - Doerholt, Katja

AU - Ghosn, Jade

AU - Bucher, Heiner C

AU - Lundgren, Jens D

AU - Chene, Genevieve

AU - Miro, Jose M

AU - Furrer, Hansjakob

AU - Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.

AB - Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.

KW - AIDS-Related Opportunistic Infections

KW - Adult

KW - Anti-HIV Agents

KW - Antifungal Agents

KW - CD4 Lymphocyte Count

KW - Europe

KW - Female

KW - HIV Infections

KW - Humans

KW - Incidence

KW - Male

KW - Middle Aged

KW - Pneumocystis jirovecii

KW - Pneumonia, Pneumocystis

KW - Risk Factors

U2 - 10.1086/655761

DO - 10.1086/655761

M3 - Journal article

C2 - 20645862

SN - 1058-4838

VL - 51

SP - 611

EP - 619

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 5

ER -